LevitasBio Completes Series C Financing
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"This funding furthers our plans to become the benchmark platform for sample processing workflows," stated Joe Walthers, LevitasBio VP of Finance. "Our existing life sciences and pharmaceutical development clients overwhelmingly validated the power and success of our technology."
Martin Pieprzyk, CEO of LevitasBio, expounded that "Unlike current industry methods that induce alterations, stress or damage that mask the true biology of your sample, LevitasBio solutions preserve the key biological signatures that deliver the most viable and unaltered cells, providing researchers clearer data for actionable insights. I believe LevitasBio is expertly positioned to become the de facto industry standard for cellular analysis."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
MENLO PARK, Calif. -- Businesswire -- LevitasBio, Inc., www.levitasbio.com, a premier end-to-end sample processing and analysis provider to the life sciences market, announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis.
The funding allows LevitasBio to accelerate its commercial success through the development of next generation high-throughput instruments for sample processing and analysis. For the first time ever, researchers using LevitasBio’s groundbreaking technology can examine, analyze and understand true biological signatures without altering, stressing, or damaging cells—all while preserving the original samples.
This new round of funding was led by Novalis Lifesciences with the participation of Pavilion Capital—a unit of Temasek Holdings Pte, an industry-leading strategic investor, and was supported by existing investor Decheng Capital.
“This funding furthers our plans to become the benchmark platform for sample processing workflows,” stated Joe Walthers, LevitasBio VP of Finance. “Our existing life sciences and pharmaceutical development clients overwhelmingly validated the power and success of our technology.”
“Novalis is excited to support LevitasBio as it transforms sample processing and analysis. This critical part of the workflow has stymied industry innovation and is underappreciated by the investment community,” said Paul Meister, Partner at Novalis LifeSciences. ”We are impressed with LevitasBio‘s unique solutions that have been commercialized thus far and, with our investment, will enable their revolutionary advancement of sample preparation and analysis that powers life science research.’'
Over the last year LevitasBio expanded its impressive portfolio with multiple product developments:
· LeviPrep—novel and empowering cold tissue dissociation kits · LeviSelect—specific surface marker enrichment assays · LeviCell EOS System—next generation sample processing platform with higher throughput and temperature control · LeviMetrics—integrated analysis software for real-time on-platform analysis
Martin Pieprzyk, CEO of LevitasBio, expounded that “Unlike current industry methods that induce alterations, stress or damage that mask the true biology of your sample, LevitasBio solutions preserve the key biological signatures that deliver the most viable and unaltered cells, providing researchers clearer data for actionable insights. I believe LevitasBio is expertly positioned to become the de facto industry standard for cellular analysis.”
LevitasBio—True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
About Novalis LifeSciences LLC
Novalis LifeSciences is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. The firm has approximately $500M in assets under management in two investment funds.
www.novalislifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005087/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:LevitasBio, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 유럽무대에 오른 ‘2024 모꼬지 대한민국’ 현지 언론도 큰 관심 - 뉴스와이어
- 현대자동차, 수소전기차 콘셉트카 공개 - 뉴스와이어
- 현대로템, 첨단 무인 소방로봇 최초 공개 - 뉴스와이어
- 동원그룹, 계열사 신규 대표이사 선임… 현장·전문성에 방점 - 뉴스와이어
- 로우퀘스트 ‘김혜윤 효과’로 매출 179% 성장에 초고속 품절까지 - 뉴스와이어
- LG생활건강, 미국 벤처캐피탈 ‘드레이퍼 스타트업 하우스’와 글로벌 뷰티테크 스타트업 육성 -
- 파인인포, 에센코어 클레브 M.2 NVMe PCle Gen4x4 CRAS C910 4TB 출시 - 뉴스와이어
- 삼성전자 Neo QLED 8K·뮤직 프레임, 미국 타임 올해 최고의 발명품 선정 - 뉴스와이어
- 아모레퍼시픽그룹, 2024년 3분기 경영 성과 발표 - 뉴스와이어
- 하트-하트재단 주최, 현대백화점그룹 후원 ‘2024 H-라이징 콘서트’ - 뉴스와이어